JodiIanLuchsMD

Ophthalmology • Stuart, FL

Anterior Segment Related, Cataract Related, Cornea & External Disease, Refractive Surgery

Director of Cornea/External Disease: Florida Vision Institute; Chief Science Advisor: InFocus Capital Partners; Director: Stuart Therapeutics

Join to view full profile

Dr. Luchs is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Luchs' full profile

Already have an account?

Office
1050 SE Monterey Rd
Ste 104
Stuart, FL 34994
Phone+1 772-283-2020

Fax+1 772-220-9582

Education & Training

Sidney Kimmel Medical College at Thomas Jefferson University/Wills Eye HospitalFellowship, Cornea, External Diseases, and Refractive Surgery, 1995 - 1996
Zucker School of Medicine at Hofstra/NorthwellResidency, Ophthalmology, 1992 - 1995
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalInternship, Internal Medicine, 1991 - 1992
Albert Einstein College of MedicineClass of 1991
Sidney Kimmel Medical College at Thomas Jefferson University/TJUHFellowship, Wills Eye Hospital

Certifications & Licensure

NY State Medical License 1992 - 2026
FL State Medical License 2018 - 2025
PA State Medical License 1995 - 1996
American Board of Ophthalmology Ophthalmology

Awards, Honors, & Recognition

Achievement Award American Academy of Ophthalmology, 2017
Fellow (FAAO) American Academy of Ophthalmology

Clinical Trials

Safety and Efficacy of Optive in Contact Lens Wearers With Dry Eyes Start of enrollment: 2007 May 01
Completed
Phase 4
A Comparison of the RPS Adeno Detector IV to Viral Cell Culture at Detecting Adenoviral Conjunctivitis Start of enrollment: 2009 Jun 01
Completed
Not Applicable
Cross-linking of Corneal Collagen (CXL) With Ultraviolet-A in Asymmetric Corneas Start of enrollment: 2010 Feb 01
Terminated
Dry Eye Assessment and Management Study Start of enrollment: 2014 Nov 01
Completed
Phase 3
Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease Start of enrollment: 2014 Jun 01
Completed
Phase 2
Safety and Efficacy of KPI-121 in Subjects With Inflammatory Meibomian Gland Disease Start of enrollment: 2014 Jul 01
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Effect of OTX-101 in Patients with Dry Eye Disease at Day 14 of Treatment: Ocular Surface Endpoint Results from the Phase 2b/3 Clinical Trial.
Barry A Schechter, Maitee Urbieta, Jason Bacharach, Melissa Toyos, Robert Smyth-Medina
Clinical Ophthalmology. 2022-01-01
4 citations
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca.
John D. Sheppard, M.T. Bergmann, Barry A. Schechter, Jodi Luchs, Abayomi Ogundele
Clinical Ophthalmology. 2021-01-12
5 citations
Late-onset fungal interface keratitis following endothelial keratoplasty with positive donor fungal culture.
Kenneth A Beckman, Mark S. Milner, Parag A. Majmudar, Jodi Luchs
American Journal of Ophthalmology Case Reports. 2020-06-01

Press Mentions

FDA OKs New Dry Eye TreatmentAugust 20th, 2018
Sun Pharma Announces U.S. FDA Approval of CEQUA™ to Treat Dry Eye DiseaseAugust 16th, 2018

Professional Memberships